In addition, the current mainstay treatment regimens of RA such as methotrexate, leflunomide, and anti-tumor necrosis factor-α (TNF-α) agents might play a possible role in lung injury and exacerbation of existing ILD [22–24]. The gene discussed is TNF; the disease is rheumatoid arthritis.